Quote this publication Share Print

CETINOR (sildenafil), phosphodiesterase type 5 inhibitor

UROLOGY - New medicinal product
Opinions on drugs - Posted on May 10 2017

Reason for request


For this generic version of VIAGRA, no clinical added value demonstrated in erectile dysfunction.


  • CETINOR has marketing authorisation in adult men with erectile dysfunction.
  • It is a 1st-line medicine that has no clinical added value compared with other phosphodiesterase type 5 inhibitors (CIALIS, LEVITRA, SPEDRA).
  • Reimbursement is recommended only in men whose erectile dysfunction is very likely to be causally related to a serious and defined organic disease.



Clinical Benefit




Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments